Research & Development

The landscape of hematological oncology is currently witnessing a transformative shift as clinicians move beyond traditional chemotherapy toward precision-engineered cellular therapies that can distinguish between malignant and healthy tissues with unprecedented accuracy. This evolution is

The persistent evolution of drug-resistant tumors has long remained the primary barrier to achieving a definitive cure for lung cancer patients who initially respond well to therapy. While modern medicine successfully transformed many terminal diagnoses into manageable chronic conditions, certain

A routine dinner featuring raw oysters or a medium-rare burger might seem like a standard indulgence for most, yet for a growing segment of the global population, these meals represent a dangerous biological gamble. While a healthy individual might experience a brief bout of gastrointestinal

Within the microscopic theater of the human body, a relentless surveillance network operates with such precision that most pathogens are neutralized long before symptoms ever appear. At the heart of this defensive perimeter are dendritic cells, the primary "sentinels" that bridge the gap between

The precision required to dismantle a tumor without devastating the surrounding healthy tissue remains one of the most elusive targets in modern oncology. While the pharmaceutical industry has long sought to perfect antibody-drug conjugates (ADCs), the technical reality often falls short of the

Ivan Kairatov brings a wealth of expertise to the table as a seasoned biopharma strategist with a specialized focus on the intersection of metabolic research and regulatory innovation. With years of experience navigating the complex R&D pipelines of the world’s leading pharmaceutical firms, he has